ERIN MUNOZ: Open Payments
NPI 1144519927 · WEBSTER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,180 in 58 payments from 22 companies in 2025. Trend: 2023 $1,478 · 2024 $628 · 2025 $1,180
Food & beverage: $1,180
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $168 |
| Neurocrine BioSciences, Inc. | 4 | $140 |
| Novo Nordisk Inc | 4 | $93 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $81 |
| Aimmune Therapeutics, Inc. | 3 | $66 |
| VIVUS LLC | 3 | $65 |
| TOLMAR, INC. | 3 | $63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
Products named: INGREZZA, VRAYLAR, Kerendia, CAPLYTA, ZENPEP, PANCREAZE, JATENZO, XIFAXAN.
Industry payments across TX — which companies pay providers there.
